Canaccord raised the firm’s price target on Koru Medical (KRMD) to $4 from $3 and keeps a Buy rating on the shares. The firm said this was the company’s third consecutive quarter of double digit growth with strength in its domestic core business as they continues to outpace the US core SCIg market while it grew nearly 300% in its Novel Therapies business given clinical trial orders and NRE milestone progress.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KRMD:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue